SensoDetect to Present at Redeye Theme: Medtech & Diagnostics
Presentation date and time: 2025-11-12 at 09:25
Format: 12 min presentation + 8 min Q&A
Language: English
Event page and livestream
https://www.redeye.se/events/1110236/redeye-theme-medtech-diagnostics-4
This is the 12th annual Redeye event focusing on the Medtech & Diagnostics sector. The program begins with a market introduction by Redeye’s analysts, followed by presentations from selected companies at varying stages of development. A number of investors will attend onsite, and the event will also be streamed live. Viewers may submit questions directly through the event page, with Q&A moderated by Redeye’s analyst team.
PA Hedin, CEO SensoDetect AB, comments
“SensoDetect is now advancing toward scaled deployment. We continue to build momentum through clinical data, international partnerships, and concrete implementation pathways. We will trough our presentation “We Measure What Others Cannot — Scaling the Global Standard in Neuro-Auditory Brain Screening show the market on our progress and new strategic direction.”
Dr. Mohamed Hussein Atwa, Global Head of Clinical Research, adds
“Our clinical work continues to demonstrate strong consistency and applicability across regions. The interest we are receiving from private schools and public health stakeholders reflects both medical need and the practicality of our approach.”
A recording of the presentation will be made available through Redeye’s platform after the event.
For more information or partnership inquiries, please contact:
PA Hedin, CEO Sensodetect AB
+46 (0)46 15 79 04
pa.hedin@sensodetect.com
SensoDetect AB is a MedTech AI company listed on the Spotlight Stock Market, focused on establishing the global standard for objective neuro-auditory brain screening. The company’s technology is based on more than 30 years of research in clinical psychoacoustics and neuroscience from Lund University and is protected by a strong international patent portfolio.
SensoDetect’s core platform uses brainstem auditory response patterns to objectively measure neural function in minutes. The method supports large-scale screening and clinical decision-making in conditions such as ADHD, autism spectrum disorder and other neurodevelopmental and psychiatric conditions—providing measurable signals where traditional diagnostic tools rely heavily on subjective assessment.
In recent years, the company has advanced from research to commercial deployment through strategic partnerships and clinical programs in Europe, the Middle East, and China. The latest generation of the system, including BERA 4.2 and integrated AI analysis, enables faster testing, greater scalability, and the ability to support national-level screening initiatives in healthcare, schools, and preventive medicine.
SensoDetect’s mission is to increase diagnostic accuracy, reduce waiting times, and support healthcare systems in managing the rapidly growing global need for mental and neurodevelopmental health evaluation. The company aims to make objective brain screening accessible at scale—improving outcomes for patients, families, and society.
More info at https://www.sensodetect.com/